prednisone has been researched along with Neuroblastoma in 26 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Neuroblastoma: A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eligible subjects were randomized to receive twelve cycles of IVIG (IVIG+) or no IVIG (NO-IVIG) in addition to prednisone and neuroblastoma risk-adapted chemotherapy." | 9.27 | Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. ( Cohn, SL; de Alarcon, PA; Hogarty, MD; London, WB; Maris, JM; Matthay, KK; Naranjo, A; Panzer, JA; Park, JR; Tenney, SC, 2018) |
| "Eligible subjects were randomized to receive twelve cycles of IVIG (IVIG+) or no IVIG (NO-IVIG) in addition to prednisone and neuroblastoma risk-adapted chemotherapy." | 5.27 | Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. ( Cohn, SL; de Alarcon, PA; Hogarty, MD; London, WB; Maris, JM; Matthay, KK; Naranjo, A; Panzer, JA; Park, JR; Tenney, SC, 2018) |
| "Twenty-six children greater than 1 year of age with previously untreated stage IV neuroblastoma were randomized to receive either a five-drug regimen (prednisone, cyclophosphamide, actinomycin D, vincristine, and daunorubicin) or a two-drug regimen (cyclophosphamide and vincristine)." | 5.04 | Phase II study demonstrating failure of both a five-drug continuous-therapy regimen and a two-drug pulse-therapy regimen in the treatment of metastatic neuroblastoma: Southwest Oncology Group Study 822. ( Doering, EJ; George, S; Haggard, ME; Land, VJ; Morgan, SK; Nitschke, R; Starling, K; Williams, T, 1979) |
| "Opsoclonus-myoclonus-ataxia syndrome (OMA) in children is most commonly associated with occult neuroblastoma (NB)." | 1.33 | Late presentation of opsoclonus-myoclonus-ataxia syndrome in a child with stage 4S neuroblastoma. ( Johnston, DL; Mutch, LS, 2005) |
| "When a neuroblastoma was present, tumor removal did not improve symptoms." | 1.29 | Outcome of children with opsoclonus-myoclonus regardless of etiology. ( Hammer, MS; Larsen, MB; Stack, CV, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (61.54) | 18.7374 |
| 1990's | 5 (19.23) | 18.2507 |
| 2000's | 2 (7.69) | 29.6817 |
| 2010's | 2 (7.69) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Yadav, SP | 1 |
| Wadhwa, T | 1 |
| Thakkar, D | 1 |
| Kapoor, R | 1 |
| Rastogi, N | 1 |
| Sarma, S | 1 |
| de Alarcon, PA | 1 |
| Matthay, KK | 1 |
| London, WB | 1 |
| Naranjo, A | 1 |
| Tenney, SC | 1 |
| Panzer, JA | 1 |
| Hogarty, MD | 1 |
| Park, JR | 1 |
| Maris, JM | 1 |
| Cohn, SL | 1 |
| Kushner, BH | 1 |
| Khakoo, Y | 1 |
| D ANGIO, GJ | 1 |
| MIUS, A | 1 |
| EVANS, AE | 1 |
| Mutch, LS | 1 |
| Johnston, DL | 1 |
| Aguila, B | 1 |
| Coulbault, L | 1 |
| Boulouard, M | 1 |
| Léveillé, F | 1 |
| Davis, A | 1 |
| Tóth, G | 1 |
| Borsodi, A | 1 |
| Balboni, G | 1 |
| Salvadori, S | 1 |
| Jauzac, P | 1 |
| Allouche, S | 1 |
| Grubb, BP | 1 |
| Thant, M | 1 |
| Platt, MS | 1 |
| Agamanolis, DP | 1 |
| Krill, CE | 1 |
| Boeckman, C | 1 |
| Potter, JL | 1 |
| Robinson, H | 1 |
| Lloyd, J | 1 |
| Hammer, MS | 1 |
| Larsen, MB | 1 |
| Stack, CV | 1 |
| Zemlickis, D | 1 |
| Lishner, M | 1 |
| Erlich, R | 1 |
| Koren, G | 1 |
| Einhorn, LH | 1 |
| Doering, EJ | 1 |
| Nitschke, R | 1 |
| Haggard, ME | 1 |
| Land, VJ | 1 |
| Morgan, SK | 1 |
| Starling, K | 1 |
| Williams, T | 1 |
| George, S | 1 |
| Sitarz, AL | 1 |
| Santulli, TV | 1 |
| Wigger, HJ | 1 |
| Berdon, WE | 1 |
| Domeyer, C | 1 |
| Schulte-Overberg, U | 1 |
| Boll, I | 1 |
| Baumgarten, E | 1 |
| Bührer, C | 1 |
| Fengler, R | 1 |
| Henze, G | 1 |
| Spitzer, G | 1 |
| Müller, KM | 1 |
| Nykyri, E | 1 |
| Andersson, LC | 1 |
| Suganuma, Y | 1 |
| Ise, T | 1 |
| Akiyama, Y | 1 |
| Bessho, F | 1 |
| Fukazawa, K | 1 |
| Hirotsu, T | 1 |
| Kitamura, T | 1 |
| Koide, A | 1 |
| Matsuyama, K | 1 |
| Muchi, H | 1 |
| Stald, G | 1 |
| Egli, F | 1 |
| Ching, LT | 1 |
| Burgert, EO | 1 |
| Mills, SD | 1 |
| Jaffe, N | 2 |
| Traggis, D | 1 |
| Das, L | 1 |
| Moloney, WC | 1 |
| Hann, HW | 1 |
| Kim, BS | 1 |
| Nair, R | 1 |
| Larbre, F | 1 |
| Bethenod, M | 1 |
| Guibaud, P | 1 |
| Mamelle, JC | 1 |
| Genoud, J | 1 |
| Lawhorn, TI | 1 |
| Stone, HH | 1 |
| Martin, JD | 1 |
| Dubois-Ferrière, H | 1 |
| Schläpfer, A | 1 |
| Bamatter, F | 1 |
| Finklestein, JZ | 1 |
| Ekert, H | 1 |
| Isaacs, H | 1 |
| Higgins, G | 1 |
| Moe, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone[NCT00033293] | Phase 3 | 53 participants (Actual) | Interventional | 2004-03-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Bayley Scales of infant development mental scale best score of two time points will be used in the analysis. For a given patient, this score will be used to calculate the change from baseline." (NCT00033293)
Timeframe: Changes from baseline to the better of 6 months or 1 year
| Intervention | Change in Bayley's score (Mean) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 117.5 |
| Arm II (Chemotherapy, Observation) | 100.75 |
"The best score at the two time points will be used in this analysis. For a given patient, this best score will be used to calculate the change from baseline. The mean change from baseline for each treatment group will be calculated." (NCT00033293)
Timeframe: Changes from baseline to the better of 6 months or 1 year
| Intervention | Change in VABS score (Mean) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 84.53 |
| Arm II (Chemotherapy, Observation) | 144.73 |
A multi-stage design followed by a test of proportions between the treatment arms (chemo vs. chemo + therapeutic immune globulin (IVIG)) will be performed. The first stage of the multi-stage design will also function as an early stopping rule for insufficient activity of chemotherapy in OMA. (NCT00033293)
Timeframe: Changes from baseline to 2 months, 6 months, and 1 year
| Intervention | participants (Number) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 21 |
| Arm II (Chemotherapy, Observation) | 11 |
EFS rate for neuroblastoma event from time of study enrollment. (NCT00033293)
Timeframe: Up to 3 years
| Intervention | 3 year EFS (Number) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 92.3 |
| Arm II (Chemotherapy, Observation) | 96.0 |
OS rate from time of study enrollment. (NCT00033293)
Timeframe: Up to 3 years
| Intervention | 3 year OS (Number) |
|---|---|
| Arm I (Chemotherapy, Immunoglobulin Therapy) | 100 |
| Arm II (Chemotherapy, Observation) | 96.0 |
2 reviews available for prednisone and Neuroblastoma
| Article | Year |
|---|---|
Autotransplantation in solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1991 |
Chemotherapy in solid tumors of childhood.
Topics: Abdominal Neoplasms; Adolescent; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Eye Neopla | 1972 |
3 trials available for prednisone and Neuroblastoma
| Article | Year |
|---|---|
Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Child; Child, Pres | 2018 |
Phase II study demonstrating failure of both a five-drug continuous-therapy regimen and a two-drug pulse-therapy regimen in the treatment of metastatic neuroblastoma: Southwest Oncology Group Study 822.
Topics: Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Daunorubicin; Drug Evaluation; Drug Therapy, | 1979 |
Autotransplantation in solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1991 |
22 other studies available for prednisone and Neuroblastoma
| Article | Year |
|---|---|
COVID-19 reinfection in two children with cancer.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carboplatin; Child, Presch | 2021 |
Enigmatic entities: opsoclonus myoclonus ataxia syndrome linked to neuroblastoma.
Topics: Ataxia; Child; Humans; Immunoglobulins, Intravenous; Neuroblastoma; Opsoclonus-Myoclonus Syndrome; P | 2018 |
THE SUPERIOR MEDIASTINAL SYNDROME IN CHILDREN WITH CANCER.
Topics: Adolescent; Child; Hodgkin Disease; Humans; Leukemia; Lymphoma; Lymphoma, Non-Hodgkin; Mediastinal N | 1965 |
Late presentation of opsoclonus-myoclonus-ataxia syndrome in a child with stage 4S neuroblastoma.
Topics: Ataxia; Humans; Immunoglobulins, Intravenous; Infant; Male; Neuroblastoma; Paraneoplastic Syndromes, | 2005 |
In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance.
Topics: Animals; Antidepressive Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bind | 2007 |
Neuroblastoma in an adult.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Th | 1984 |
Occult hepatic sinusoid tumor of infancy simulating neuroblastoma.
Topics: Drug Therapy, Combination; Female; Follow-Up Studies; Hepatomegaly; Humans; Infant; Liver Neoplasms; | 1983 |
Outcome of children with opsoclonus-myoclonus regardless of etiology.
Topics: Adrenocorticotropic Hormone; Child, Preschool; Developmental Disabilities; Epilepsies, Myoclonic; Fe | 1995 |
Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adrenal Gland Neoplasms; Adult; Aminopterin; A | 1993 |
Cancer chemotherapy.
Topics: Chlorambucil; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Female; Hodgkin Disease; Humans; Leuk | 1977 |
Complete maturation of neuroblastoma with bone metastases in documented stages.
Topics: Bone Neoplasms; Child, Preschool; Cyclophosphamide; Female; Ganglioneuroma; Humans; Infant; Mercapto | 1975 |
Erythroblastopenia in two patients after splenectomy and polychemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cross Infection; C | 1991 |
Effect of thymectomy and immunosuppressive therapy on anti-neuroblastoma antibody levels in patients with myasthenia gravis.
Topics: Adolescent; Adult; Aged; Autoantibodies; Azathioprine; Cell Line; Female; Follow-Up Studies; Humans; | 1991 |
[Clinical evaluation of cisplatin in children with malignant solid tumors. Pediatric Cisplatin Study Group].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Chi | 1987 |
[Therapy of malignant tumors in childhood].
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Child, Preschool; Eosinophilic Granuloma; Histio | 1969 |
Chemotherapeutic agents in childhood malignancies.
Topics: Alkaloids; Alkylating Agents; Anti-Bacterial Agents; Antimetabolites; Asparaginase; Child; Humans; L | 1970 |
L-asparaginase in the treatment of neoplastic diseases in children.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Marrow Examination; Bone Neoplasms; Burkitt Ly | 1971 |
[Oculo-cerebello-myoclonic syndrome and neuroblastoma. Apropos of 2 cases].
Topics: Abdominal Neoplasms; Adrenocorticotropic Hormone; Catecholamines; Diazepam; Epinephrine; Eye Movemen | 1972 |
Pediatric oncology.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Asparaginase; Child; Child, Prescho | 1973 |
[Cytologic modifications of acute myeloblastic leukemia and sympathicogonioma treated with Cerubidine].
Topics: Adult; Antineoplastic Agents; Child, Preschool; Drug Synergism; Erythrocytes; Humans; Leukemia, Myel | 1968 |
Bone marrow metastases in children with solid tumors.
Topics: Bone Marrow Diseases; Bone Marrow Examination; Bone Neoplasms; Child; Cyclophosphamide; Dactinomycin | 1970 |
Serum haptoglobin level in disseminated malignant diseases in children.
Topics: Aminopterin; Child; Child, Preschool; Diagnosis, Differential; Haptoglobins; Hematologic Diseases; H | 1970 |